SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 6.75% Stake in FibroGen, Inc.
Beneficial Ownership Disclosure
Investment firm Armistice Capital, LLC and its managing member Steven Boyd have disclosed a 6.75% beneficial ownership stake in FibroGen, Inc., holding 6,800,000 shares as of December 31, 2024.
Summary
- Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in FibroGen, Inc.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 6,800,000 shares of FibroGen, Inc.'s Common Stock, representing 6.75% of the class.
- Armistice Capital, LLC, a Delaware entity, serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
- Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is deemed to beneficially own the securities held by the Master Fund.
- The beneficial ownership percentage is calculated based on 100,770,153 shares outstanding as of October 31, 2024, as reported in FibroGen's 10-Q filed on November 12, 2024.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a standard regulatory disclosure of beneficial ownership, which is neutral in sentiment. It indicates a significant, passive investment stake.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant passive ownership stake by an investment firm in a publicly traded biotechnology company. It does not provide specific insights into broader industry trends or competitive positioning beyond the fact of investment interest in FibroGen, Inc.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.
- Company Management: Awareness of a substantial passive shareholder, though the filing states no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 10/31/2024 | Date as of which 100,770,153 shares outstanding were reported in FibroGen's 10-Q. |
| 11/12/2024 | Date FibroGen's 10-Q was filed with the SEC, reporting shares outstanding. |
| 12/31/2024 | Date of event which requires filing of this statement (beneficial ownership snapshot). |
| 02/14/2025 | Date the Schedule 13G/A Amendment No. 2 was signed and filed. |
Keywords
FibroGen, Armistice Capital, Steven Boyd, Beneficial Ownership, Schedule 13G, Common Stock, Investment Management, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.